Pentraxin 3: A promising therapeutic target for autoimmune diseases

Wu, Qian; Cao, Fan; Tao, Jin‐Hui; Li, Xiaomei; Zheng, Song Guo; Pan, Hai‐Feng

doi:10.1016/j.autrev.2020.102584

Cited by 46 publications

(42 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the treatment of autoimmune diseases mainly relied on non-specific immunosuppression ( Wu et al, 2020 ) Despite there were various important breakthroughs in therapeutic medicine, especially with respect to biologics, insufficient selection of targets often led to suboptimal effects, systemic adverse effect and patient nonadherence. The mechanisms of other autoimmune diseases were still being explored.…”

Section: Introductionmentioning

confidence: 99%

The Role of IL-36 in the Pathophysiological Processes of Autoimmune Diseases

Chen

Yuan

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

A member of the interleukin (IL)-1 superfamily was IL-36, which contained IL-36α, IL-36β, IL-36γ, and IL-36Ra. Heterotrimer complexes, consisting of heterodimeric receptor complexes and IL-36 agonist, gave signals through intracellular functional domains, so as to bind to downstream proteins and induce inflammatory response. IL-36 agonists upregulated mature-associated CD80, CD86, MHCII, and inductively produced several pro-inflammatory cytokines through the IL-36R-dependent manner in dendritic cells (DCs). Besides, DCs had the ability to initiate the differentiation of helper T (Th) cells. Up to date, the role of IL-36 in immunity, inflammation and other diseases is of great importance. Additionally, autoimmune diseases were characterized by excessive immune response, resulting in damage and dysfunction of specific or multiple organs and tissues. Most autoimmune diseases were related to inflammatory response. In this review, we will conclude the recent research advances of IL-36 in the occurrence and development of autoimmune diseases, which may provide new insight for the future research and the treatment of these diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of IL-36 in the Pathophysiological Processes of Autoimmune Diseases

Chen

Yuan

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…miR-21 was found to be significantly elevated in SSc fibroblasts and to regulate TGF-β-regulated fibrosis-related gene expression ( Zhu et al, 2013 ) and collagen expression ( Jafarinejad-Farsangi et al, 2019 ). PTX3 (pentraxin 3) serves as a biomarker for several autoimmune diseases ( Wu et al, 2020 ), participating in inflammation regulation and fibrocyte differentiation. PTX3 was elevated in the serum ( Shirai et al, 2015 ) and fibroblasts ( Luchetti et al, 2004 ) of SSc patients.…”

Section: Discussionmentioning

confidence: 99%

Prediction of a Competing Endogenous RNA Co-expression Network by Comprehensive Methods in Systemic Sclerosis-Related Interstitial Lung Disease

Yan

Zheng

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is an immune-mediated connective tissue disease characterized by fibrosis of multi-organs, and SSc-related interstitial lung disease (SSc-ILD) is a leading cause of morbidity and mortality. To explore molecular biological mechanisms of SSc-ILD, we constructed a competing endogenous RNA (ceRNA) network for prediction. Expression profiling data were obtained from the Gene Expression Omnibus (GEO) database, and differential expressed mRNAs and miRNAs analysis was further conducted between normal lung tissue and SSc lung tissue. Also, the interactions of miRNA–lncRNA, miRNA–mRNA, and lncRNA–mRNA were predicted by online databases including starBase, LncBase, miRTarBase, and LncACTdb. The ceRNA network containing 11 lncRNAs, 7 miRNAs, and 20 mRNAs were constructed. Based on hub genes and miRNAs identified by weighted correlation network analysis (WGCNA) method, three core sub-networks—SNHG16, LIN01128, RP11-834C11.4(LINC02381)/hsa-let-7f-5p/IL6, LINC01128/has-miR-21-5p/PTX3, and LINC00665/hsa-miR-155-5p/PLS1—were obtained. Combined with previous studies and enrichment analyses, the lncRNA-mediated network affected LPS-induced inflammatory and immune processes, fibrosis development, and tumor microenvironment variations. The ceRNA network, especially three core sub-networks, may be served as early biomarkers and potential targets for SSc, which also provides further insights into the occurrence, progression, and accurate treatment of SSc at the molecular level.

show abstract

“…PTX3 was originally discovered in 1992 and is a member of the orthopentamerin family. It is a typical acute-phase protein that is expressed by hematopoietic cells and stromal cells in response to primary proinflammatory stimuli, and it is essential for innate immune humoral immunity, with involvement in the identification of pathogens, inflammation regulation and tissue remodeling [ 52 – 54 ]. Studies in tumors showed that PTX3 promoted cell migration and invasion, and its expression level was related to the progression of different tumor types in humans.…”

Section: Discussionmentioning

confidence: 99%

Pentraxin 3 is a diagnostic and prognostic marker for ovarian epithelial cancer patients based on comprehensive bioinformatics and experiments

Chang

Liu

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Background Ovarian epithelial cancer is one of the leading malignant tumors in gynecology and lacks effective diagnostic and prognostic markers. Our study aims to screen and verify ovarian epithelial cancer biomarkers. Methods GSE18520 and GSE26712 were downloaded from the GEO database. The “limma” and “WGCNA” packages were used to explore hub genes. The Kaplan–Meier Plotter database was used for survival analysis of the hub genes. Immunohistochemical analysis was used to identify the expression level of Pentraxin 3 in ovarian epithelial cancer samples. Results In this study, we integrated and analyzed two datasets, GSE18520 and GSE26712, and a total of 238 differentially expressed genes (DEGs) were screened out. Enrichment analysis showed that these DEGs were related to collagen-containing extracellular matrix and other pathways. Further application of WGCNA (weighted gene coexpression network analysis) identified 15 gene modules, with the purple module showing the highest correlation with ovarian epithelial cancer. Twenty-five genes were shared between the purple module and DEGs, 13 genes were related to the prognosis of ovarian epithelial cancer patients, and the PTX3 gene had the highest hazardous risk (HR) value. We performed immunohistochemical analyses on the 255 Pentraxin-3 (PTX3)-based clinical samples. PTX3 was found to be overexpressed in ovarian epithelial cancer and related to the degree of differentiation. The Cox proportional hazard model indicates that high PTX3 expression is an independent risk factor for the prognosis of ovarian epithelial cancer patients. Conclusions In conclusion, through WGCNA and a series of comprehensive bioinformatics analyses, PTX3 was first identified as a novel diagnostic and prognostic biomarker for ovarian epithelial cancer.

show abstract

Pentraxin 3: A promising therapeutic target for autoimmune diseases

Cited by 46 publications

References 120 publications

The Role of IL-36 in the Pathophysiological Processes of Autoimmune Diseases

The Role of IL-36 in the Pathophysiological Processes of Autoimmune Diseases

Prediction of a Competing Endogenous RNA Co-expression Network by Comprehensive Methods in Systemic Sclerosis-Related Interstitial Lung Disease

Pentraxin 3 is a diagnostic and prognostic marker for ovarian epithelial cancer patients based on comprehensive bioinformatics and experiments

Contact Info

Product

Resources

About